Guggenheim analyst Yatin Suneja downgraded Sage Therapeutics to Neutral from Buy with no price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SAGE:
- Sage Therapeutics management to meet with Piper Sandler
- Biogen and Sage Therapeutics to hold a joint investor webcast
- Sage Therapeutics, Biogen complete NDA to FDA for zuranolone
- Sage Therapeutics (NASDAQ:SAGE) Rises as CEO Loads Up On Stock
- Sage Therapeutics price target lowered to $50 from $55 at H.C. Wainwright